Jefferies Financial Group Inc. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 84,902 shares of the medical research company's stock, valued at approximately $16,405,000. Jefferies Financial Group Inc. owned 0.05% of IQVIA at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in IQVIA during the 2nd quarter valued at about $2,811,292,000. Boston Partners purchased a new position in shares of IQVIA in the third quarter worth about $676,698,000. Norges Bank acquired a new stake in shares of IQVIA during the fourth quarter worth about $497,445,000. Victory Capital Management Inc. boosted its position in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock valued at $377,670,000 after buying an additional 1,614,063 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in IQVIA in the 2nd quarter worth approximately $240,911,000. Hedge funds and other institutional investors own 89.62% of the company's stock.
Insiders Place Their Bets
In related news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company's stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the business's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares of the company's stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,913 shares of company stock valued at $3,098,793 over the last ninety days. 1.70% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Morgan Stanley reissued an "equal weight" rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Weiss Ratings raised shares of IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada lifted their price objective on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $241.88.
View Our Latest Stock Analysis on IQV
IQVIA Trading Up 0.3%
IQV stock opened at $262.18 on Friday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $265.25. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $43.15 billion, a P/E ratio of 32.53, a PEG ratio of 2.23 and a beta of 1.18. The company's 50-day simple moving average is $220.29 and its 200-day simple moving average is $189.12.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.
IQVIA announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.
About IQVIA
(
Free Report)
IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
